Matches in SemOpenAlex for { <https://semopenalex.org/work/W2030333482> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2030333482 endingPage "148" @default.
- W2030333482 startingPage "148" @default.
- W2030333482 abstract "toxicity with imaging every 8 weeks. The primary endpoint was PFS. Serum and tumor samples were collected for biomarker analyses. Pretreatment serum proteomic test (VeriStrat) was performed blinded to clinical data. Results: 192 pts were enrolled from 2/2010 to 2/2011. Erlotinib/pazopanib resulted in a statistically significant improvement in PFS compared with erlotinib alone: HR 0.59 (95%CI, 0.43–0.83), P=.0016. OS was similar between arms: HR 1.1 (0.77–1.55), P=.61. Pretreatment serum was available for 90 pts; 64 pts were classified as VeriStrat ‘Good’ and 26 as ‘Poor’. Baseline characteristics for these classified groups were well balanced with the rest of study population: 66% treated with erlotinib/ pazopanib, 78% nonsquamous histology, and 22% current smokers. Notably, more ‘Good’ classified pts had an ECOG PS of 0 than ‘Poor’: 38% v. 12%. ‘Good’ pts treated with erlotinib/pazopanib had a better PFS than ‘Good’ pts treated with erlotinib alone, HR 0.47 (0.25–0.86), P=.015. Additionally, ‘Good’ pts treated with erlotinib/pazopanib had a better PFS and OS than ‘Poor’ pts treated with erlotinib/pazopanib, PFS: HR 0.34 (0.18–0.65), P=.001; OS: HR 0.25 (0.13–0.48), P < 0.0001. In multivariate analysis, only proteomic classification and treatment were significant for PFS, and proteomic classification alone was significant for OS. Conclusions: Baseline serum proteomic classification identified pts with improved PFS and OS from combined treatment with erlotinib and pazopanib. Prospective studies using proteomic classification to assign optimal treatment are in progress." @default.
- W2030333482 created "2016-06-24" @default.
- W2030333482 creator A5006624933 @default.
- W2030333482 creator A5011137037 @default.
- W2030333482 creator A5022323779 @default.
- W2030333482 creator A5028938155 @default.
- W2030333482 creator A5031266401 @default.
- W2030333482 creator A5046971770 @default.
- W2030333482 creator A5050356586 @default.
- W2030333482 creator A5068993095 @default.
- W2030333482 date "2012-11-01" @default.
- W2030333482 modified "2023-09-26" @default.
- W2030333482 title "477 pERK Expression in Erlotinib-treated Patients with Advanced Pancreatic Cancer: a Translational Subgroup Analysis From the Randomized AIO-PK0104 Phase III Trial" @default.
- W2030333482 doi "https://doi.org/10.1016/s0959-8049(12)72275-x" @default.
- W2030333482 hasPublicationYear "2012" @default.
- W2030333482 type Work @default.
- W2030333482 sameAs 2030333482 @default.
- W2030333482 citedByCount "0" @default.
- W2030333482 crossrefType "journal-article" @default.
- W2030333482 hasAuthorship W2030333482A5006624933 @default.
- W2030333482 hasAuthorship W2030333482A5011137037 @default.
- W2030333482 hasAuthorship W2030333482A5022323779 @default.
- W2030333482 hasAuthorship W2030333482A5028938155 @default.
- W2030333482 hasAuthorship W2030333482A5031266401 @default.
- W2030333482 hasAuthorship W2030333482A5046971770 @default.
- W2030333482 hasAuthorship W2030333482A5050356586 @default.
- W2030333482 hasAuthorship W2030333482A5068993095 @default.
- W2030333482 hasConcept C121608353 @default.
- W2030333482 hasConcept C126322002 @default.
- W2030333482 hasConcept C143998085 @default.
- W2030333482 hasConcept C168563851 @default.
- W2030333482 hasConcept C187960798 @default.
- W2030333482 hasConcept C2778087573 @default.
- W2030333482 hasConcept C2779438470 @default.
- W2030333482 hasConcept C2780210213 @default.
- W2030333482 hasConcept C31760486 @default.
- W2030333482 hasConcept C535046627 @default.
- W2030333482 hasConcept C71924100 @default.
- W2030333482 hasConcept C95190672 @default.
- W2030333482 hasConceptScore W2030333482C121608353 @default.
- W2030333482 hasConceptScore W2030333482C126322002 @default.
- W2030333482 hasConceptScore W2030333482C143998085 @default.
- W2030333482 hasConceptScore W2030333482C168563851 @default.
- W2030333482 hasConceptScore W2030333482C187960798 @default.
- W2030333482 hasConceptScore W2030333482C2778087573 @default.
- W2030333482 hasConceptScore W2030333482C2779438470 @default.
- W2030333482 hasConceptScore W2030333482C2780210213 @default.
- W2030333482 hasConceptScore W2030333482C31760486 @default.
- W2030333482 hasConceptScore W2030333482C535046627 @default.
- W2030333482 hasConceptScore W2030333482C71924100 @default.
- W2030333482 hasConceptScore W2030333482C95190672 @default.
- W2030333482 hasLocation W20303334821 @default.
- W2030333482 hasOpenAccess W2030333482 @default.
- W2030333482 hasPrimaryLocation W20303334821 @default.
- W2030333482 hasRelatedWork W2039780710 @default.
- W2030333482 hasRelatedWork W2057074797 @default.
- W2030333482 hasRelatedWork W2163866397 @default.
- W2030333482 hasRelatedWork W2168849655 @default.
- W2030333482 hasRelatedWork W2394079738 @default.
- W2030333482 hasRelatedWork W2421782557 @default.
- W2030333482 hasRelatedWork W2507295142 @default.
- W2030333482 hasRelatedWork W2588553327 @default.
- W2030333482 hasRelatedWork W2752933315 @default.
- W2030333482 hasRelatedWork W3150367784 @default.
- W2030333482 hasVolume "48" @default.
- W2030333482 isParatext "false" @default.
- W2030333482 isRetracted "false" @default.
- W2030333482 magId "2030333482" @default.
- W2030333482 workType "article" @default.